Nuveen LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Nuveen LLC acquired 48,601 shares of ANI Pharmaceuticals, valued at approximately $3,254,000, increasing its ownership to 0.22% of the company.
• Several institutional investors, including Millennium Management LLC and GAMMA Investing LLC, significantly increased their stakes in ANI Pharmaceuticals, contributing to a total of 76.05% of the company's stock held by institutional investors.
• ANI Pharmaceuticals reported impressive quarterly earnings, with an EPS of $1.80, surpassing estimates, and revenue of $211.37 million, a year-over-year increase of 53.2%.

Nuveen LLC purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 48,601 shares of the specialty pharmaceutical company's stock, valued at approximately $3,254,000. Nuveen LLC owned approximately 0.22% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Principal Financial Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 68.3% during the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock worth $10,565,000 after buying an additional 64,021 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of ANI Pharmaceuticals by 53.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock worth $599,000 after buying an additional 3,112 shares in the last quarter. Invesco Ltd. raised its holdings in shares of ANI Pharmaceuticals by 1.0% during the 1st quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock worth $13,361,000 after buying an additional 2,022 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in ANI Pharmaceuticals by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock worth $15,959,000 after acquiring an additional 2,220 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ANIP. Piper Sandler restated an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Truist Financial boosted their price objective on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. HC Wainwright restated a "buy" rating and set a $93.00 price objective (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Finally, Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of "Buy" and an average target price of $84.75.

ANI Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ ANIP traded up $0.82 during trading on Wednesday, reaching $94.92. The company had a trading volume of 523,839 shares, compared to its average volume of 739,339. The company's fifty day moving average price is $75.06 and its 200-day moving average price is $67.74. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $95.60. The stock has a market cap of $2.06 billion, a P/E ratio of -123.27 and a beta of 0.63. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same quarter in the previous year, the company posted $1.02 EPS. The business's revenue was up 53.2% on a year-over-year basis. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In other news, Director Matthew J. Leonard sold 2,528 shares of the business's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $90.62, for a total value of $229,087.36. Following the transaction, the director directly owned 6,864 shares of the company's stock, valued at $622,015.68. The trade was a 26.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Muthusamy Shanmugam sold 52,988 shares of the business's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $90.44, for a total value of $4,792,234.72. Following the completion of the transaction, the chief operating officer directly owned 431,920 shares in the company, valued at $39,062,844.80. This represents a 10.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 405,538 shares of company stock worth $35,690,131. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.